RESUMEN
RATIONALE: The prognosis of lung cancer is dismal, which has resulted in lung carcinoma being one of the leading causes of cancer-related deaths worldwide. Non-small cell lung cancer accounts for approximately 80% of all types of lung carcinoma. The skeletal system and central nervous system are the most common distal metastatic sites in patients with lung cancer, while cutaneous and soft tissues metastasis is rare. PATIENT CONCERNS: We report a case of concomitant metastasis in the nasal tip and suspected buttocks metastasis secondary to lung cancer, who complained of repeated cough and white sputum for 6 months. DIAGNOSE: Primary lung cancer was diagnosed by bronchoscopy and biopsy, lesion on nasal tip was confirmed by biopsy. Furthermore, PET-CT scan identified the untouchable buttocks lesion that could have been easily missed. INTERVENTIONS: This patient refused systemic treatments, but he chose traditional Chinese medicine at home. OUTCOMES: He died 6 months after the diagnosis. LESSONS: The possibility of metastasis of primary cancers should be considered when encountering soft-tissue neoplasm lesions, and a biopsy of the suspicious cutaneous lesions could likely aid in the histological identification of the primary cancer. PET-CT scan could be an effective supplementary tool for the diagnosis and evaluation of cancers.
Asunto(s)
Neoplasias Pulmonares/patología , Neoplasias Cutáneas/secundario , Neoplasias de los Tejidos Blandos/secundario , Humanos , Neoplasias Pulmonares/diagnóstico por imagen , Masculino , Persona de Mediana Edad , Tomografía Computarizada por Tomografía de Emisión de PositronesRESUMEN
Invasive cutaneous melanoma is a growing health concern. Although surgical excision can effectively treat in situ tumors, use for metastatic melanoma is limited. Laser and light-based therapies may be a valuable palliative treatment option for patients with stage III and stage IV cutaneous metastatic melanoma. Our goal is to review the published literature and provide evidence-based recommendations on laser and light-based palliative therapies for metastatic melanoma. A search of the databases Pubmed, EMBASE, Web of Science, and CINAHL was performed on March 10, 2016. Key search terms were related to melanoma, laser, and light-based modalities. Our search initially identified 13,923 articles and 27 original articles met inclusion criteria for our review. Grade of recommendation: C for non-fractionated carbon dioxide laser, Grade of recommendation: D for fractionated carbon dioxide laser, ruby laser, neodymium laser, near-infrared diode laser, and photodynamic therapy. Non-fractionated carbon dioxide laser had the best palliative efficacy of the reviewed laser and light-based therapies, while other treatment modalities may have potential as adjunctive therapy to standard of care.
Asunto(s)
Terapia por Láser , Melanoma/terapia , Fototerapia , Neoplasias de los Tejidos Blandos/terapia , Terapia Combinada , Humanos , Láseres de Gas , Melanoma/patología , Cuidados Paliativos , Neoplasias Cutáneas , Neoplasias de los Tejidos Blandos/secundario , Melanoma Cutáneo MalignoAsunto(s)
Antineoplásicos/uso terapéutico , Bencenosulfonatos/uso terapéutico , Carcinoma Neuroendocrino/tratamiento farmacológico , Metástasis de la Neoplasia/tratamiento farmacológico , Piridinas/uso terapéutico , Neoplasias de la Tiroides/tratamiento farmacológico , Adulto , Neoplasias Óseas/tratamiento farmacológico , Neoplasias Óseas/secundario , Carcinoma Neuroendocrino/complicaciones , Carcinoma Neuroendocrino/secundario , Humanos , Inmunohistoquímica , Neoplasias Pulmonares/tratamiento farmacológico , Neoplasias Pulmonares/secundario , Metástasis Linfática/patología , Masculino , Neoplasias del Mediastino/tratamiento farmacológico , Neoplasias del Mediastino/secundario , Metástasis de la Neoplasia/patología , Niacinamida/análogos & derivados , Compuestos de Fenilurea , Tomografía de Emisión de Positrones , Esquistosomiasis/complicaciones , Neoplasias Cutáneas/tratamiento farmacológico , Neoplasias Cutáneas/secundario , Neoplasias de los Tejidos Blandos/tratamiento farmacológico , Neoplasias de los Tejidos Blandos/secundario , Sorafenib , Neoplasias de la Tiroides/complicaciones , Neoplasias de la Tiroides/patologíaAsunto(s)
Enfermedad Hepática Inducida por Sustancias y Drogas/etiología , Nerium/efectos adversos , Extractos Vegetales/efectos adversos , Sarcoma Sinovial , Neoplasias de los Tejidos Blandos , Adulto , Antineoplásicos/uso terapéutico , Resultado Fatal , Femenino , Humanos , Inyecciones Intramusculares , Articulación de la Rodilla , Neoplasias Pulmonares/secundario , Sarcoma Sinovial/patología , Neoplasias de los Tejidos Blandos/secundarioRESUMEN
OBJECTIVE: To determine if sorafenib is associated with an improved 4-month probability of progression-free survival, using radiographic and clinical criteria alone, in patients with metastatic castration-resistant prostate cancer. Secondary endpoints included pharmacokinetics, toxicity analysis and overall survival. PATIENTS AND METHODS: The study was an open-label, phase II, two-stage design, focusing on the results from the second stage, as criteria for progression were modified after completing the first stage. Sorafenib was given at a dose of 400 mg orally twice daily in 28-day cycles. Clinical and laboratory assessments were done every 4 weeks, and radiographic scans were obtained every 8 weeks. RESULTS: Twenty-four patients were accrued in the second stage; the median (range) age was 66 (49-85) years, the on-study prostate-specific antigen level was 68.45 (5.8-995) ng/mL, the Gleason score 8 (6-9) and Eastern Cooperative Oncology Group status 1 (in 17 patients). Of the 24 patients, 21 had previous chemotherapy with docetaxel. All patients had bony metastases, either alone (in 11) or with soft-tissue disease (in 13). One patient had a partial response; 10 patients had stable disease (median duration 18 weeks, range 15-48). At a median potential follow-up of 27.2 months, the median progression-free survival was 3.7 months and the median overall survival was 18.0 months. For the whole trial of 46 patients the median survival was 18.3 months. Most frequent toxicities included hand-foot skin reaction (grade 2 in nine patients, grade 3 in three), rash, abnormalities in liver function tests, and fatigue. CONCLUSIONS: Sorafenib has moderate activity as a second-line treatment for metastatic castration-resistant prostate cancer.
Asunto(s)
Antineoplásicos/uso terapéutico , Bencenosulfonatos/uso terapéutico , Neoplasias Óseas/tratamiento farmacológico , Neoplasias de la Próstata/tratamiento farmacológico , Piridinas/uso terapéutico , Neoplasias de los Tejidos Blandos/tratamiento farmacológico , Anciano , Anciano de 80 o más Años , Antineoplásicos/efectos adversos , Bencenosulfonatos/efectos adversos , Neoplasias Óseas/mortalidad , Neoplasias Óseas/secundario , Supervivencia sin Enfermedad , Hormona Liberadora de Gonadotropina/uso terapéutico , Humanos , Masculino , Persona de Mediana Edad , Metástasis de la Neoplasia , Niacinamida/análogos & derivados , Orquiectomía , Compuestos de Fenilurea , Neoplasias de la Próstata/mortalidad , Neoplasias de la Próstata/cirugía , Piridinas/efectos adversos , Neoplasias de los Tejidos Blandos/mortalidad , Neoplasias de los Tejidos Blandos/secundario , Sorafenib , Resultado del Tratamiento , Quinasas raf/antagonistas & inhibidoresAsunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Tumor Carcinoide/terapia , Neoplasias del Recto/terapia , Recto/cirugía , Neoplasias de los Tejidos Blandos/secundario , Camptotecina/administración & dosificación , Camptotecina/análogos & derivados , Quimioterapia Adyuvante , Supervivencia sin Enfermedad , Femenino , Fluorouracilo/administración & dosificación , Humanos , Irinotecán , Leucovorina/administración & dosificación , Persona de Mediana Edad , Inducción de Remisión , Neoplasias de los Tejidos Blandos/terapia , Factores de Tiempo , Resultado del TratamientoRESUMEN
Sixty-three patients received capecitabine at 1000 mg/m2 twice daily every 2 out of 3 weeks as first-line treatment for advanced disease at our institution. Forty-five patients (71%) had previously received adjuvant or neoadjuvant chemotherapy. The median number of capecitabine cycles administered was 5(1-40). Forty-eight patients had measurable disease with response rate (RR) of 29%. The median time to progression (TTP) was 18(2-122) weeks. Seven patients (11%) had TTP of >1 yr, four of whom received more than 10(24-40) cycles of capecitabine. Thirty-seven percent of patients still needed dose reductions. Our retrospective audit is consistent with a previously published study which used a higher starting dose of capecitabine as first-line chemotherapy. For a subgroup of patients, capecitabine can result in a long TTP with minimal toxicity. The benefit of continuing capecitabine beyond a fixed number of cycles should be investigated further. Schedules using even lower doses of capecitabine for longer periods may also be of interest.
Asunto(s)
Antimetabolitos Antineoplásicos/administración & dosificación , Neoplasias Óseas/tratamiento farmacológico , Neoplasias de la Mama/tratamiento farmacológico , Desoxicitidina/análogos & derivados , Fluorouracilo/análogos & derivados , Neoplasias de los Tejidos Blandos/tratamiento farmacológico , Vísceras , Adulto , Anciano , Neoplasias Óseas/secundario , Neoplasias de la Mama/patología , Capecitabina , Desoxicitidina/administración & dosificación , Relación Dosis-Respuesta a Droga , Esquema de Medicación , Femenino , Fluorouracilo/administración & dosificación , Estudios de Seguimiento , Humanos , Persona de Mediana Edad , Estudios Retrospectivos , Neoplasias de los Tejidos Blandos/secundario , Resultado del TratamientoRESUMEN
BACKGROUND: Clouston syndrome is an autosomal dominant disorder characterized by nail dystrophy, partial or total alopecia, and hyperkeratosis of the palms and soles. OBJECTIVE: Although a variety of unusual cutaneous manifestations have been described, the incidence of melanoma in this population is unknown. METHODS: This article reports a case of in-transit metastatic subungual melanoma in a patient with Clouston syndrome successfully treated with hyperthermic limb perfusion with melphalan. RESULTS: Six months postperfusion, the patient is doing well, with resolution of the extremity erythema and edema. Followup ultrasonography revealed reduction in size of the eight subcutaneous nodules, with the largest measuring 3.3 cm in maximum diameter, representing nearly a 50% reduction in tumor volume postperfusion. CONCLUSION: Although melanoma has also been associated with some forms of ectodermal dysplasia, such as ectrodactyly--ectodermal dysplasia--clefting (EEC) syndrome, the incidence of melanoma in patients with Clouston syndrome is unknown. Thus far, to our knowledge, this is the first case report of melanoma arising in a patient with Clouston syndrome.
Asunto(s)
Quimioterapia del Cáncer por Perfusión Regional/métodos , Displasia Ectodérmica/genética , Hipertermia Inducida , Melanoma/terapia , Recurrencia Local de Neoplasia/terapia , Neoplasias Cutáneas/terapia , Neoplasias de los Tejidos Blandos/terapia , Adulto , Antineoplásicos Alquilantes/uso terapéutico , Displasia Ectodérmica/complicaciones , Femenino , Humanos , Extremidad Inferior , Melanoma/complicaciones , Melanoma/genética , Melanoma/secundario , Melfalán/uso terapéutico , Neoplasias Cutáneas/complicaciones , Neoplasias Cutáneas/genética , Neoplasias Cutáneas/patología , Neoplasias de los Tejidos Blandos/complicaciones , Neoplasias de los Tejidos Blandos/genética , Neoplasias de los Tejidos Blandos/secundario , Resultado del TratamientoRESUMEN
A 2.5-cm diameter, exophytic seeding of hepatocellular carcinoma was detected by contrast-enhanced computed tomography in a 76-year-old man. He had previously undergone a radiofrequency ablation therapy with an expandable, ten-hook needle electrode for the treatment of a 1.5-cm hepatocellular carcinoma in liver segment VI. Ultrasound-guided fine needle biopsy revealed that this hepatocellular carcinoma was moderately differentiated, as initial tumor was. An additional radiofrequency ablation achieved complete ablation of this neoplastic mass on contrast-enhanced computed tomography scanning. Recurrences were not found for eight months after. To prevent tumor seeding, using thermocoagulation when retracting the needle electrode may be useful.
Asunto(s)
Carcinoma Hepatocelular/secundario , Electrodos/efectos adversos , Hipertermia Inducida/instrumentación , Neoplasias Hepáticas/terapia , Agujas/efectos adversos , Siembra Neoplásica , Neoplasias de los Tejidos Blandos/secundario , Anciano , Biopsia con Aguja , Carcinoma Hepatocelular/diagnóstico por imagen , Carcinoma Hepatocelular/terapia , Humanos , Hipertermia Inducida/efectos adversos , Neoplasias Hepáticas/diagnóstico por imagen , Masculino , Retratamiento , Neoplasias de los Tejidos Blandos/diagnóstico por imagen , Neoplasias de los Tejidos Blandos/terapia , Tomografía Computarizada por Rayos XRESUMEN
There is currently no curative therapy for men who have disseminated prostate cancer following failed radical prostatectomy. The purpose of this trial was to investigate systemic radioimmunotherapy in these men. Eight patients with occult metastatic prostate cancer following radical prostatectomy as evidenced solely by a rising serum PSA and evidence of soft tissue lesions outside the prostatic fossa detected by an [111I]indiumcapromab pendetide scan received an infusion of 10 mg of capromab pendetide labeled with 9 mCi/m2 of [90Y]yttrium. Serum PSA was used to measure response rate. There were no complete or partial responses by PSA criteria. Significant unexpected bone marrow toxicity developed in the first 6 of 8 patients treated. The last two patients received co-infusion of edetate calcium disodium in an effort to decrease marrow suppression. In these two patients less marrow toxicity was seen. Repeat 111In-capromab pendetide scans were uninterpretable due to grossly altered whole-body biodistribution of the radioimmunoconjugate. Retrospective analysis of serial PSA values after closure of the study showed a decrease in the log slope PSA for seven of eight patients following radioimmunotherapy, with a statistically significant change in the mean log slope (p = 0.01). The clinical significance of this small but measurable change is uncertain. We conclude that radioimmunotherapy for occult metastatic prostate cancer using 90Y-capromab-pendetide at the dose described does not lower serum PSA, is associated with significant hematologic toxicity, and leads to complexation of the immunoconjugate following subsequent capromab pendetide infusion.
Asunto(s)
Adenocarcinoma/radioterapia , Adenocarcinoma/secundario , Anticuerpos Monoclonales/uso terapéutico , Inmunoconjugados/uso terapéutico , Leucopenia/etiología , Neoplasias de la Próstata/cirugía , Terapia Recuperativa , Neoplasias de los Tejidos Blandos/secundario , Trombocitopenia/etiología , Radioisótopos de Itrio/uso terapéutico , Adenocarcinoma/sangre , Adenocarcinoma/diagnóstico por imagen , Anciano , Anticuerpos Monoclonales/efectos adversos , Anticuerpos Monoclonales/inmunología , Antineoplásicos Hormonales/uso terapéutico , Biomarcadores de Tumor/sangre , Médula Ósea/efectos de los fármacos , Médula Ósea/efectos de la radiación , Terapia Combinada , Ácido Edético/administración & dosificación , Ácido Edético/uso terapéutico , Hormona Liberadora de Gonadotropina/agonistas , Humanos , Inmunoconjugados/efectos adversos , Masculino , Persona de Mediana Edad , Antígeno Prostático Específico/sangre , Antígeno Prostático Específico/inmunología , Prostatectomía , Neoplasias de la Próstata/patología , Traumatismos por Radiación/etiología , Radioinmunodetección , Neoplasias de los Tejidos Blandos/sangre , Neoplasias de los Tejidos Blandos/diagnóstico por imagen , Neoplasias de los Tejidos Blandos/radioterapia , Distribución Tisular , Tomografía Computarizada de Emisión de Fotón Único , Tomografía Computarizada por Rayos X , Insuficiencia del Tratamiento , Resultado del Tratamiento , Radioisótopos de Itrio/efectos adversosRESUMEN
Hyperthermic isolated limb perfusion (HILP) with tumor necrosis factor alpha (TNFalpha) is effective for advanced melanoma and sarcoma of the limbs. Ten patients undergoing HILP with TNFalpha were evaluated by neurological examinations, nerve conduction studies (NCS), sympathetic skin responses (SSR) and conventional and quantitative electromyography (EMG), performed before, 7 days and 6 weeks following HILP. Seven patients showed minimal clinical signs of peripheral nerve damage following HILP; in two the injury was evident electrophysiologically: 7 days following HILP five patients had paresthesias and/or hypoesthesia, one had a mild foot drop and one had autonomic disturbances in the affected limb. SSR was low in two patients in the affected limb, sensory nerve action potentials were not elicited in one, with normal motor NCS and EMG. At 6 weeks, four patients continued to have mild paresthesias and one had dysautonomia of the perfused limb. Sensory responses and SSR did not change, motor abnormalities were not found. These findings show that HILP with TNFalpha induces a mild, mainly sensory neuropathy in perfused limbs, not disturbing functionality and improving over time.
Asunto(s)
Brazo/inervación , Enfermedades del Sistema Nervioso Autónomo/inducido químicamente , Factores Inmunológicos/efectos adversos , Pierna/inervación , Melanoma/secundario , Parestesia/inducido químicamente , Enfermedades del Sistema Nervioso Periférico/inducido químicamente , Sarcoma de Kaposi/secundario , Neoplasias de los Tejidos Blandos/secundario , Factor de Necrosis Tumoral alfa/efectos adversos , Adulto , Anciano , Anciano de 80 o más Años , Antineoplásicos Alquilantes/administración & dosificación , Antineoplásicos Alquilantes/uso terapéutico , Quimioterapia del Cáncer por Perfusión Regional , Terapia Combinada , Electromiografía , Femenino , Humanos , Hipertermia Inducida , Factores Inmunológicos/administración & dosificación , Factores Inmunológicos/farmacología , Factores Inmunológicos/uso terapéutico , Masculino , Melanoma/terapia , Melfalán/administración & dosificación , Melfalán/uso terapéutico , Persona de Mediana Edad , Conducción Nerviosa/efectos de los fármacos , Pronóstico , Reflejo Anormal , Sarcoma de Kaposi/terapia , Neoplasias de los Tejidos Blandos/terapia , Factor de Necrosis Tumoral alfa/administración & dosificación , Factor de Necrosis Tumoral alfa/farmacología , Factor de Necrosis Tumoral alfa/uso terapéuticoRESUMEN
From May 1981 to September 1991, 38 patients with metastatic malignant melanoma were treated with combined radiation therapy and hyperthermia to a total of 97 hyperthermia treatment fields. Prior treatments to these sites included surgery (31 patients, 76 fields), chemotherapy (18 patients, 54 fields), immunotherapy (14 patients, 42 fields) and radiation therapy (7 patients, 13 hyperthermia fields). Hyperthermia was given to fields located in the head and neck region, trunk and extremities in 30, 45 and 22 cases, respectively. Nodular-diffuse tumours were present in 86 fields while 11 fields were treated for microscopic residual tumour deposits. Concurrent radiation therapy was given in 180-400 cGy per fraction, 2-5 times per week for a mean total dose of 4098 cGy per field. Hyperthermia treatments were delivered using either microwave or ultrasound devices (286 and 48 treatments, respectively) with a mean (range) of 3.4 (1-14) hyperthermia treatments per field for a mean (range) of 43 (10-70) min per field. Patients (n = 34; 84 fields) were available for follow-up for a mean (range) of 14.6 (0.4-82.5) months. At 3 weeks post-treatment, 34 fields had complete, ongoing, or partial responses; 39 fields had no response; and there were no recurrences in the 11 fields treated for microscopic residual disease. Local control was maintained in 31% (26/84) fields with a mean follow-up of 14.6 months. At 36 months, five patients remained alive with complete control of their treated local disease. Statistical analyses revealed that patients with soft tissue metastases only, who were older at the time of hyperthermia, had a longer time between initial diagnosis and hyperthermia treatment, received a higher dose of radiation, had no previous chemotherapy, and had small tumour volumes, had a higher initial response. Multivariate analyses revealed that the three-covariate model including time interval between initial diagnosis and hyperthermia treatment, previous chemotherapy, and metastases to soft tissue only, best predicted response. The results of the investigation support the continued study of combined radiation therapy and hyperthermia treatments for selected patients with metastatic melanoma, and indicate that long-term survival can occasionally be obtained with this approach.
Asunto(s)
Hipertermia Inducida , Melanoma/radioterapia , Melanoma/terapia , Adulto , Anciano , Anciano de 80 o más Años , Terapia Combinada , Femenino , Humanos , Masculino , Melanoma/secundario , Persona de Mediana Edad , Análisis Multivariante , Pronóstico , Dosificación Radioterapéutica , Recurrencia , Neoplasias de los Tejidos Blandos/radioterapia , Neoplasias de los Tejidos Blandos/secundario , Neoplasias de los Tejidos Blandos/terapia , Factores de TiempoRESUMEN
Patients must be followed up closely after primary therapy for invasive breast cancer so that locoregional recurrences can be detected early. Once a recurrence has been detected, a thorough evaluation is indicated to exclude distant metastatic disease. If none is found, the patient may be a candidate for aggressive surgical intervention to render the patient disease-free. If distant disease is found, certain sites, such as the CNS or long bones, may warrant aggressive therapy because failure to treat these sites may lead to excessive morbidity. In most situations, patients with distant disease are treated with palliative measures. In selected instances, however, patients with metastatic breast cancer are candidates for aggressive intervention, including pulmonary or liver resection or high-dose chemotherapy in combination with autologous bone marrow transplantation, to rid the patient of the disease.
Asunto(s)
Neoplasias de la Mama/patología , Neoplasias de la Mama/cirugía , Recurrencia Local de Neoplasia , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Trasplante de Médula Ósea , Neoplasias Óseas/secundario , Neoplasias de la Mama/diagnóstico , Neoplasias del Sistema Nervioso Central/secundario , Cisplatino/administración & dosificación , Terapia Combinada , Ciclofosfamida/administración & dosificación , Doxorrubicina/administración & dosificación , Femenino , Fluorouracilo/administración & dosificación , Humanos , Neoplasias Hepáticas/secundario , Neoplasias Pulmonares/secundario , Mastectomía/métodos , Metotrexato/administración & dosificación , Metástasis de la Neoplasia , Recurrencia Local de Neoplasia/diagnóstico , Recurrencia Local de Neoplasia/cirugía , Recurrencia Local de Neoplasia/terapia , Cuidados Paliativos , Radioterapia , Neoplasias de los Tejidos Blandos/secundarioRESUMEN
Fifty patients with advanced breast cancer were treated by high dose cisplatin (DDP) combination chemotherapy during the period of August 1984 to June 1991. All of them had measurable disease. Among the fifty patients, 24 had previously received chemotherapy. DDP was given at a dose of 50-128 mg/m2 intravenously every 3 weeks. The regimen was PCMF (DDP + CTX + MTX + 5FU), PA (DDP+ADM) +/- other agents or PF (DDP + 5FU) +/- other agents. The overall response rate was 76% (38/50) with a CR rate of 20% (10/50). The median response duration and median survival time were 5.5 months and 15 months, respectively. Best response was obtained in soft tissue metastasis (83.3%, 40/48), and in lung metastasis (79.3%, 23/29). The response rate was lower in liver metastasis (40%, 2/5) and lowest in bone metastasis (0/9). Marked gastrointestinal reaction was observed in most patients (84%). These results indicate that high dose cisplatin combination chemotherapy is an effective regimen for advanced breast cancer.
Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Neoplasias de la Mama/tratamiento farmacológico , Cisplatino/administración & dosificación , Neoplasias de los Tejidos Blandos/secundario , Adulto , Neoplasias Óseas/tratamiento farmacológico , Neoplasias Óseas/secundario , Cisplatino/efectos adversos , Ciclofosfamida/administración & dosificación , Femenino , Fluorouracilo/administración & dosificación , Humanos , Neoplasias Pulmonares/tratamiento farmacológico , Neoplasias Pulmonares/secundario , Masculino , Metotrexato/administración & dosificación , Persona de Mediana Edad , Náusea/inducido químicamente , Neoplasias de los Tejidos Blandos/tratamiento farmacológicoRESUMEN
Patients with gastric adenocarcinoma typically present with symptoms that include anorexia, early satiety, and weight loss. Although the disease may already be far advanced at presentation, signs and symptoms from involvement of skeletal muscle are extremely uncommon. In fact, metastatic cancer of any type to the skeletal muscles is rare, and most of these metastases are discovered at autopsy. We report here the case of a 65-yr-old man who presented with complaints of weight loss, early satiety, bloating, and swelling and tenderness in his upper thighs. Endoscopy with biopsy revealed invasive, poorly differentiated gastric adenocarcinoma. Biopsy of one of the thigh masses displayed the same findings. The patient initially responded well to an investigational protocol with high-dose 5-fluorouracil, with regression of the thigh masses and palliation of his pain.
Asunto(s)
Adenocarcinoma/secundario , Neoplasias de los Tejidos Blandos/secundario , Neoplasias Gástricas/patología , Muslo , Adenocarcinoma/tratamiento farmacológico , Adenocarcinoma/patología , Anciano , Fluorouracilo/uso terapéutico , Humanos , Masculino , Neoplasias Gástricas/tratamiento farmacológicoAsunto(s)
Hipertermia Inducida , Neoplasias de los Tejidos Blandos/terapia , Terapia Combinada , Estudios de Evaluación como Asunto , Humanos , Microondas , Recurrencia Local de Neoplasia/radioterapia , Recurrencia Local de Neoplasia/terapia , Cuidados Paliativos , Neoplasias de los Tejidos Blandos/radioterapia , Neoplasias de los Tejidos Blandos/secundarioRESUMEN
Twenty-six patients with advanced melanoma metastases confined to the lower extremity underwent 28 therapeutic limb perfusions without a major complication or treatment-related death. A complete response to treatment occurred in 21 patients (81 percent). Of 16 patients, response persisted until death in 13 and was noted at 75, 87, and 96 months follow-up in 3. In five patients, response lasted a median of 5 months (range 3 to 14 months), and repeat perfusion in two of these patients was not beneficial. Unfortunately, despite locoregional disease control, most patients died from distant metastases at a median of 15 months after treatment. In fact, regardless of response to perfusion, the 3 year survival rate of patients with advanced metastatic melanoma of the extremity was only 25 percent or less. Thus, although limb perfusion can be a safe and highly effective means of achieving locoregional disease control, there appears to be little survival benefit. Therefore, perfusion should be reserved for palliative treatment of selected patients with locally advanced melanoma.
Asunto(s)
Hipertermia Inducida/métodos , Pierna , Melanoma/terapia , Recurrencia Local de Neoplasia/terapia , Neoplasias Primarias Múltiples/terapia , Neoplasias Cutáneas/terapia , Adulto , Anciano , Femenino , Estudios de Seguimiento , Humanos , Hipertermia Inducida/instrumentación , Masculino , Melanoma/secundario , Persona de Mediana Edad , Neoplasias de los Tejidos Blandos/secundario , Neoplasias de los Tejidos Blandos/terapiaRESUMEN
From June 1973 to May 1978 a total of 845 patients with operable breast cancer were entered into different adjuvant programs. The medical records of the 278 patients showing relapse were carefully re-evaluated to assess the pattern(s) of first recurrence and the consistency of follow-up modulation. Ninety-one of 179 patients treated with surgery alone, 130 of 414 given 12 cycles of adjuvant CMF and 57 of 252 treated with 6 cycles of CMF showed treatment failure within 5 years from radical mastectomy. The frequency of new disease manifestations was significantly affected by primary treatment, since patients given adjuvant CMF showed a lower tendency to recur in local-regional area(s) and in bone(s). However, in relapsed patients, patterns of new lesions were not substantially altered by type of primary treatment. The most frequently involved sites were soft tissues (37.8%) and bones (37%) followed by viscera (34.2%). Retrospective evaluation of X-rays revealed that in 26.2% of osseous metastases, diagnosis could have been assessed earlier, with a median delay of 4 months (range 1-8). Present analysis also revealed that short-term repeated X-ray examinations yielded findings more controversial than reliable for assessing the exact time of relapse, thus preventing firm conclusions in the presence of suspicious recurrence. A new follow-up schedule after completion of adjuvant chemotherapy is proposed, since on the basis of our experience, in asymptomatic patients frequently repeated examinations are not necessary and some can safely be omitted.